The integration of spatial transcriptomics and proteomics with single-cell data has uncovered preferential accumulation of CD39+PD-1+ Tregs in tumor centers or invasive margins, where they dampen effector responses (29, 39). The gene discussed is ENTPD1; the disease is neoplasm.